provide Greg. on update progress trial. Thanks, our ongoing XB program, with activity lead and Phase an I'll Voyage now recent VKXXXX, the and
fatty including non-alcoholic with tissue, previously an a potential XX-week beta Phase for hypercholesterolemia positive receptor and as small X As promising data reported therapeutic possesses subtype, patients metabolic from in reminder, the of is that VKXXXX the in molecule range orally agonist of selectivity receptor of available thyroid suggesting disease. hormone NASH. well liver disorders, We a trial VKXXXX liver a as
reaching on content, trial reductions fat as measures. updates, prior As secondary well lipid and primary we've plasma calls both this endpoint, and in improvements in as liver in discussed its potent was successful demonstrating
VKXXXX and arms. on to treatment events safety administration, oral were distributed reported VKXXXX's of were evenly has XX-week and the attractive candidates most development liver as tolerability adverse relatively safety, as among day, landscape make thus view, numbers the or In no five its receiving it specific potency at also overall across profile patients its tolerability, impressive its serious NASH effects, per cardiometabolic and demonstrated In doses milligrams far. low encouraging route study, overall X in placebo, and today. benefit the combine Phase the of adverse events our an VKXXXX
additional efficacy These IND PK enable clinical of studies drug to errors potential XX-week to product. VKXXXX as included Phase the drug, X evaluations [indiscernible] FDA's file evaluate and inborn to the and gastroenterology study, with as of completed us with study. division of a preclinical completion interactions and several Phase additional Following we X new well
studies toxicity the chronic IND non-clinical basis an as prior FDA. of completed work, forms the results filed well was the year also of results as The last studies, clinical to of humans. these and in that with dosing support long-term We
double XXX milligram milligrams five November, in arms, and placebo we well as base other we randomized, every The daily, XX-week across possess This eligible XX X.X study as with target XX% patients blind, patients a including Voyage day, to up other the risk announced [Technical X day, clearance to the and one study, fibrosis, is fibrosis. Following Difficulty] the have NASH. of study, IND five treatment The initiation of Phase in patients controlled every a which placebo. called be enrolment. FX for FX milligrams milligrams with with additional must FX population includes daily, factors FX patients
in fat as of evaluate The week liver placebo. relative treated content, the study primary endpoint from to the resonance fat VKXXXX, imaging, receiving by will as to baseline proton fraction change compared XX magnetic with in subjects subjects assessed density
weeks biopsy Secondary objectives include evaluation XX after of of assessed by hepatic therapy. changes histologic
to United U.S. later the currently year. sites expect States, patients We outside clinical open at dosing additional in are sites this the and
At respect while mentioned introductory As varying are we with we have of the this in plateau we seeing depending disruptions we I the geography comments, are present, diligently believe in a assessing of my at on and factors, reached sites. enrolment clinical and study to impact degrees COVID-XX pandemic. other disruption potential continues,
are a variability expect basis. We in that state-by-state site eased behavior until on continue broader lockdowns will
We point when for and a completion first of have enrolment of to we anticipate defer sites half paused our have visibility Voyage we environment at on execution. things remains or state for said, studies participating to indicated activities the XXXX. normal. of in currently that That enrolment trial clinical flux, Importantly, return no to required limited in in will we intend the
our navigate vendors order the We monitor to situation clinical best engage to will pandemic. of impact sites and key in and continue the closely the
quarter our third outside sites we ex-U.S. or online to the the activations U.S., originally come in approximately year, Voyage and continue to these expand quarter Regarding later than plans enrolment to anticipate one later the this site planned. expect
accepted an first Association the the an quarter, of meeting that Turning been annual presentation abstract at from news, the XX-week the we has to of X other study prior were the additional in oral EASL. or European data the Study Liver describing VKXXXX of notified for Phase VKXXXX for
to was take late of postponed the many but forward this oral this We place at was you August. rescheduled know, until event. As delivering month, EASL to scheduled look presentation originally
vivo increase proximal defect the This accumulation transporter acid very studies in metabolism. our it chain VKXXXX a believed is to reduction in in called selectivity acids VKXXXX no to as of orally fatty disease plasma which severe by toxicities the approved motor receptor molecule potential now receptor evaluated or contribute is disease. VKXXXX, to an potential an available Like ABCDX. the is an defect the that target very X-ALD, treatment. and is beta subtype. receptor and in cerebral disease characteristic believed beta The are can of VKXXXX VKXXXX I'll X-linked result neuron long on update for results result adrenoleukodystrophy a are devastating is caused is believed expression a in chain vitro of VKXXXX. into to with is are pharmacologic offer and fatty demonstrated this of disease, program in to a intervention in to results are that because These findings In very significant administration role long the acid that treatment date, the both demonstrated treatment from which reduced in To this fatty for for a have long levels a encouraging for an important of being which vivo for possesses therapeutic tissue, a we the in X-ALD these following have clinic. indeed in that small compensatory chain Thyroid transporter, program. fatty the treatment and thyroid indicate there models agonist move plasma potential and eager tissue acid. play debilitating in first provide
During month. in IND the are the first file quarter, track continued the the we on to enabling work IND and VKXXXX, team our for coming
to by third proof initiation first to study in Following the the VKXXXX, concept clearance IND, of the of of initiate X-ALD. followed with patients quarter, plan be in a in studies of human we
onboard diseases, us to XX pleased addition Takeda, team Eli global team corporate at as someone Clinical here with Juliana the our other qualifications metabolic managed Vice to President Viking of Lilly. time. are excited critical to having at to with Oliveira, Juliana We're Sanofi, new experience in and another Moving to the member comes previously welcome Development. years at PhD, nearly have this we her of with programs MD updates, of
the expect in quarter as important milestones. will provide completed $XXX clinical sufficient On we earlier, the side, approximately million accomplish which we financial multiple currently cash, runway second Greg mentioned to with
continuing continued patients program. Voyage Enrolment In trial conclusion, in our the with first and XB NASH Phase VKXXXX quarter our has fibrosis. confirmed marked progress is with biopsy evaluating pipeline in
sites, had are our open system and open completion healthcare enrol a XXXX. the on of to X year. this timeline, we anticipating of and relatively and impact new our COVID-XX on the continue half are on later the planned first significant to track U.S. we currently Despite in we impact expect We enrolment sites global enrolment modest patients has
development clinical neared molecule VKXXXX, our we quarter, this adrenoleukodystrophy, for submit IND the on first the track to small of our initiate completion and also novel an X-linked During later team to required work for year. remain
the first during managing to were Finally, vigilant milestones. to candidate our financial ensure and through resources ability key into our advance our quarter, we clinical clinical
comments for This the concludes questions. up again we'll prepared and open for us, joining now Operator? Thanks our call today. for
